List of Dyanavel Xr 10 drug patents
Dyanavel Xr 10 is owned by Tris Pharma Inc.
Dyanavel Xr 10 contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.
Dyanavel Xr 10 has a total of 3 drug patents out of which 0 drug patents have expired.
Dyanavel Xr 10 was authorised for market use on 04 November, 2021.
Dyanavel Xr 10 is available in tablet, extended release;oral dosage forms.
The generics of Dyanavel Xr 10 are possible to be released after 15 March, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(4 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic